Rohto PharmaceuticalLtd Gestione

Gestione criteri di controllo 3/4

Rohto PharmaceuticalLtd Il CEO è Yamada Kunio, nominato in Jun2009, e ha un mandato di 15.42 anni. la retribuzione annua totale è ¥ 212.00M, composta da 89.6% di stipendio e 10.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.74% delle azioni della società, per un valore di ¥ 11.18B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.7 anni e 5.4 anni.

Informazioni chiave

Yamada Kunio

Amministratore delegato

JP¥212.0m

Compenso totale

Percentuale dello stipendio del CEO	89.6%
Mandato del CEO	15.4yrs
Proprietà del CEO	1.7%
Durata media del management	2.7yrs
Durata media del Consiglio di amministrazione	5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Rohto Pharmaceutical Co.,Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 15

Rohto Pharmaceutical Co.,Ltd. (TSE:4527) Shares Could Be 25% Below Their Intrinsic Value Estimate

Nov 07

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Reasonably Well

Oct 20

Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price

Oct 06

Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Sep 22

Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Aug 25

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

Aug 11

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Jul 11

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Jun 23

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Jun 10

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

May 14

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Apr 03

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Mar 21

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Mar 07

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Feb 26

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Yamada Kunio rispetto agli utili di Rohto PharmaceuticalLtd?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	JP¥27b
Jun 30 2024	n/a	n/a	JP¥30b
Mar 31 2024	JP¥212m	JP¥190m	JP¥31b
Dec 31 2023	n/a	n/a	JP¥31b
Sep 30 2023	n/a	n/a	JP¥30b
Jun 30 2023	n/a	n/a	JP¥28b
Mar 31 2023	JP¥205m	JP¥183m	JP¥26b
Dec 31 2022	n/a	n/a	JP¥26b
Sep 30 2022	n/a	n/a	JP¥23b
Jun 30 2022	n/a	n/a	JP¥23b
Mar 31 2022	JP¥196m	JP¥178m	JP¥21b
Dec 31 2021	n/a	n/a	JP¥23b
Sep 30 2021	n/a	n/a	JP¥21b
Jun 30 2021	n/a	n/a	JP¥20b
Mar 31 2021	JP¥185m	JP¥176m	JP¥17b
Dec 31 2020	n/a	n/a	JP¥14b
Sep 30 2020	n/a	n/a	JP¥14b
Jun 30 2020	n/a	n/a	JP¥15b
Mar 31 2020	JP¥192m	JP¥179m	JP¥15b
Dec 31 2019	n/a	n/a	JP¥11b
Sep 30 2019	n/a	n/a	JP¥10b
Jun 30 2019	n/a	n/a	JP¥9b
Mar 31 2019	JP¥181m	JP¥173m	JP¥10b

Compensazione vs Mercato: La retribuzione totale di Yamada ($USD 1.37M ) è superiore alla media delle aziende di dimensioni simili nel mercato JP ($USD 920.27K ).

Compensazione vs guadagni: La retribuzione di Yamada è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Yamada Kunio (68 yo)

15.4yrs

Mandato

JP¥212,000,000

Compensazione

Mr. Yamada Kunio had been the President at Rohto Pharmaceutical Co. Ltd. since June 9, 2009 until 2019. Mr. Kunio has been the Chairman of the Board of Directors and Representative Director at Rohto Pharma...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Yamada Kunio	Chairman of the Board & CEO	15.4yrs	JP¥212.00m	1.74% ¥ 11.2b
Masashi Sugimoto	President	5.4yrs	Nessun dato	0.0075% ¥ 47.7m
Saito Masaya	EVP, CFO & Director	2.7yrs	Nessun dato	0.021% ¥ 132.0m
Shinichi Kunisaki	EVP, CTO & Director	2.7yrs	Nessun dato	0.018% ¥ 115.1m
Hideto Kamimura	Senior Executive Officer and General Manager of Marketing Division	no data	Nessun dato	0.0053% ¥ 33.7m
Yasunori Kawasaki	CHRO & Director	1.4yrs	Nessun dato	Nessun dato
Hidetoshi Segi	MD, Chief Strategy Officer & Director	2.7yrs	Nessun dato	0.0039% ¥ 25.2m

2.7yrs

Durata media

63.5yo

Età media

Gestione esperta: Il team dirigenziale di 4527 è considerato esperto (durata media dell'incarico 2.7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Yamada Kunio	Chairman of the Board & CEO	25.4yrs	JP¥212.00m	1.74% ¥ 11.2b
Masashi Sugimoto	President	5.4yrs	Nessun dato	0.0075% ¥ 47.7m
Saito Masaya	EVP, CFO & Director	13.4yrs	Nessun dato	0.021% ¥ 132.0m
Shinichi Kunisaki	EVP, CTO & Director	14.4yrs	Nessun dato	0.018% ¥ 115.1m
Yasunori Kawasaki	CHRO & Director	1.4yrs	Nessun dato	Nessun dato
Hidetoshi Segi	MD, Chief Strategy Officer & Director	6.4yrs	Nessun dato	0.0039% ¥ 25.2m
Kimura Masanori	Standing Corporate Auditor	8.4yrs	Nessun dato	0.027% ¥ 171.3m
Akie Iriyama	Independent Outside Director	5.4yrs	Nessun dato	Nessun dato
Haruka Mera	Independent Outside Director	4.4yrs	Nessun dato	Nessun dato
Tatsuo Uemura	Independent Outside Director	2.4yrs	Nessun dato	0.00044% ¥ 2.8m
Eriko Hayashi	Independent Outside director	2.4yrs	Nessun dato	Nessun dato
Maiko Katadae	Independent Outside Director	less than a year	Nessun dato	Nessun dato

5.4yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 4527 sono considerati esperti (durata media dell'incarico 5.4 anni).

Rohto PharmaceuticalLtd Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023

Less than half of directors are independent

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2022

Less than half of directors are independent

Recent updates

Rohto Pharmaceutical Co.,Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 19%

Rohto Pharmaceutical Co.,Ltd. (TSE:4527) Shares Could Be 25% Below Their Intrinsic Value Estimate

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Reasonably Well

Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price

Now 21% undervalued

Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Upcoming dividend of JP¥16.00 per share

Now 20% undervalued

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2025 Results on Nov 13, 2024

Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Rohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Second Quarter-End and Full Fiscal Year Ending March 31, 2025

Investor sentiment deteriorates as stock falls 16%

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Final dividend of JP¥15.00 announced

Now 20% undervalued

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for €30 million.

Now 21% undervalued after recent price drop

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Upcoming dividend of JP¥15.00 per share

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Now 21% undervalued after recent price drop

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Third quarter 2024 earnings released: EPS: JP¥41.92 (vs JP¥37.02 in 3Q 2023)

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024

Price target decreased by 7.5% to JP¥3,814

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 31, 2024, Payable on December 7, 2023

Price target increased by 9.4% to JP¥4,126

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023

Upcoming dividend of JP¥12.00 per share at 0.6% yield

Price target increased by 9.4% to JP¥3,999

Price target increased by 9.0% to JP¥3,884

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023

Price target decreased by 13% to JP¥3,206

Full year 2023 earnings: EPS exceeds analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023

Price target increased by 27% to JP¥3,531

Price target increased by 8.4% to JP¥2,870

Upcoming dividend of JP¥12.00 per share at 0.9% yield

Rohto Pharmaceutical Co.,Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings: Revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2023 Results on Nov 10, 2022

Upcoming dividend of JP¥20.00 per share

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week